問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Tri-Service General Hospital

List

851Cases

2020-11-20 - 2025-12-31

Phase I

A Phase 1b Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination with Other Anti-cancer Agents in Patients with Metastatic HER2-low Breast Cancer (DESTINY-Breast08)

  • Condition/Disease

    Metastatic HER2-low Breast Cancer

  • Test Drug

    Trastuzumab deruxtecan (ENHERTUR) Durvalumab (Imfinzi?) Capivasertib

Participate Sites
7Sites

Recruiting7Sites

2021-04-01 - 2022-09-30

Phase III

An Open-Label Extension Study to Investigate the Long-Term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)

  • Condition/Disease

    Primary Immune Thrombocytopenia

  • Test Drug

    Rozanolixizumab

Participate Sites
8Sites

Not yet recruiting8Sites

2013-11-01 - 2015-01-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2014-05-01 - 2018-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2013-06-01 - 2015-02-20

Phase II/III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2010-12-01 - 2012-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2016-05-04 - 2020-10-31

Phase II

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF-OF-CONCEPT TRIAL OF AC-201 CONTROLLED RELEASE TABLETS IN SUBJECTS WITH HEMOPHILIC ARTHROPATHY

  • Condition/Disease

    HEMOPHILIC ARTHROPATHY

  • Test Drug

    AC-201CR

Participate Sites
6Sites

Terminated5Sites

張家堯
Taipei Medical University Hospital

Division of Hematology & Oncology

邱世欣
Kaohsiung Municipal Gangshan Hospital

未分科

2020-10-23 - 2022-07-24

Others

A Randomized, Double-blind, Placebo-controlled Clinical Study to Explore the Mechanism of Action of ON101 Cream in Patients with Diabetic Foot Ulcers

  • Condition/Disease

    chronic diabetic foot ulcer

  • Test Drug

    ON101 cream

Participate Sites
2Sites

Recruiting2Sites

2021-07-27 - 2025-06-30

Phase II

A Phase II Study to Evaluate the Efficacy and Safety of FB825 in Adult Patients with Moderate-to-severe Allergic Asthma

  • Condition/Disease

    Allergic Asthma

  • Test Drug

    FB825

Participate Sites
17Sites

Not yet recruiting5Sites

Recruiting12Sites

2023-02-01 - 2025-06-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Not yet recruiting1Sites

Recruiting1Sites

1 67 68 69 70 71 86
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB